A Year In Review
The DDR field has experienced explosive growth, with the number of assets surging from 21 in 2014 to 398 in 2024. While established mechanisms continue to lead, new approaches and investments are driving further innovation in the space.
Stay ahead in this rapidly evolving landscape with our comprehensive review—uncover key clinical advancements, regulatory progress, and investment trends shaping the future of DDR therapies.
Download Now
Discover the latest breakthroughs in DDR development!
Beacon’s Landscape Review delves into the DDR drug pipeline, highlighting the resurgence of PARP inhibitor trials, the rise of ATR and WEE1-targeted therapies, and key clinical milestones.
Gain insights into status changes, regulatory progress, and investment trends shaping the competitive landscape.
Report Contents
The Drug Landscape
A deep dive into the developmental statuses, phases and targets of DDR assets, as well as repair pathways.
The Trial Landscape
Analysis of DDR trials, including approval rates, targets, and disease indications.
The Commercial Market
A review of the DDR deals in 2024, analyzing the top 5 deals, deal types and active drug locations.
The Future of DDRs
Drugs to watch in DDR development and trial duration insights.
Regulatory Announcements
Key DDR approvals and regulatory developments.
Previous DDR Landscape Reviews
DDR 2024 H1 Landscape Review
An analysis of the DDR landscape in H1 of 2024.
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
